AbCellera gets Health Canada nod for Phase 1 trial of ABCL635 for hot flashes

AbCellera Biologics Inc.

Received No Objection Letter from Health Canada for ABCL635, an NK3R antagonist for non-hormonal treatment of vasomotor symptoms.
Phase 1 trial to evaluate safety, PK, and PD in healthy participants and postmenopausal women with moderate-to-severe VMS.
Trial expected to begin in Q3 2025.
ABCL635 is an investigational antibody antagonist targeting NK3R, developed for hot flashes due to menopause.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.